How have PRTX shares performed in 2024?

Protalex's stock was trading at $0.0130 at the beginning of the year. Since then, PRTX stock has increased by 0.0% and is now trading at $0.0130. View the best growth stocks for 2024 here .

How were Protalex's earnings last quarter?

Protalex, Inc. (OTCMKTS:PRTX) announced its earnings results on Friday, April, 13th. The company reported ($0.06) earnings per share (EPS) for the quarter.

What other stocks do shareholders of Protalex own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Protalex investors own include Boeing (BA) , Caterpillar (CAT) , Salesforce (CRM) , Enterprise Products Partners (EPD) , Eros STX Global (EROS) , Global Payments (GPN) , Intuitive Surgical (ISRG) , NVIDIA (NVDA) , AT&T (T) and VirTra (VTSI) .

How do I buy shares of Protalex?

Shares of PRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

OTCMKTS:PRTX

Protalex (PRTX) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Free PRTX Stock Alerts

$0.01

0.00 (0.00%)

(As of 06/25/2021)

Compare

Today's Range: $0.0130
▼
$0.0130
50-Day Range: $0.0130
▼
$0.0130
52-Week Range: $0.00
▼
$0.10

Volume: N/A
Average Volume: N/A
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get Protalex alerts:

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

About Protalex Stock (OTCMKTS:PRTX)

Protalex, Inc. focuses on the development of biopharmaceutical drugs for treating autoimmune and inflammatory diseases in the United States. The company targets a range of autoimmune diseases, such as rheumatoid arthritis (RA), immune thrombocytopenia (ITP), psoriasis, myasthenia gravis, chronic idiopathic demyelinating polyneuropathy, and pemphigus. Its lead product candidate is PRTX-100, an immunomodulatory therapy, a highly-purified form of staphylococcal protein A, which is in Phase I/II open-label, dose-escalating study for the treatment of patients with persistent/chronic ITP; and Phase 1b clinical trial for the treatment of RA on methotrexate or leflunomide. The company was founded in 1999 and is based in Florham Park, New Jersey.

PRTX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

PRTX Stock News Headlines

March 23, 2024 | thetimes.co.uk

Aberystwyth to Tregaron, Ceredigion

See More Headlines

Receive PRTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Protalex and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 4/13/2018
Today: 4/18/2024
Fiscal Year End: 5/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Sector: Medical
Industry: Commercial physical research
Sub-Industry: N/A
Current Symbol: OTCMKTS:PRTX
Previous Symbol: NASDAQ:PRTX
CUSIP: N/A
CIK: 1099215
Web: www.protalex.com
Phone: 215-862-9720
Fax: 215-862-6614
Employees: 2
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: N/A
Free Float: N/A
Market Cap: N/A
Optionable: Not Optionable
Beta: N/A

Beginners Guide To Retirement Stocks

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

Mr. Arnold P. Kling Esq. (Age 63)
Pres & Director
Comp: $72k
Dr. William E. Gannon Jr.
Chief Medical Officer & Member of Scientific Advisory Board
Dr. John Bruce Lundy McClain M.D.
Medical Director & Member of Scientific Advisory Board
Dr. Michelle Catalina Ph.D.
Director of Preclinical Studies & Member of Scientific Advisory Board

Key Competitors

View All Competitors

PRTX Stock Analysis - Frequently Asked Questions

How have PRTX shares performed in 2024?: Protalex's stock was trading at $0.0130 at the beginning of the year. Since then, PRTX stock has increased by 0.0% and is now trading at $0.0130.
View the best growth stocks for 2024 here.
How were Protalex's earnings last quarter?: Protalex, Inc. (OTCMKTS:PRTX) announced its earnings results on Friday, April, 13th. The company reported ($0.06) earnings per share (EPS) for the quarter.
What other stocks do shareholders of Protalex own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Protalex investors own include Boeing (BA), Caterpillar (CAT), Salesforce (CRM), Enterprise Products Partners (EPD), Eros STX Global (EROS), Global Payments (GPN), Intuitive Surgical (ISRG), NVIDIA (NVDA), AT&T (T) and VirTra (VTSI).
How do I buy shares of Protalex?: Shares of PRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:PRTX) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial